Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: Insights from imaging

Clinical Cancer Research

Volumn 15, Issue 21, 2009, Pages 6674-6682

  O'Connor, James P B ^a   Carano, Richard A D ^b   Clamp, Andrew R ^a   Ross, Jed ^b   Ho, Calvin C K ^b   Jackson, Alan ^a   Parker, Geoff J M ^a   Rose, Chris J ^a   Peale, Franklin V ^b   Friesenhahn, Michel ^b   Mitchell, Claire L ^a   Watson, Yvonne ^a   Roberts, Caleb ^a   Hope, Lynn ^a   Cheung, Sue ^a   Reslan, Hani Bou ^b   Go, Mary Ann T ^b   Pacheco, Glenn J ^b   Wu, Xiumin ^b   Cao, Tim C ^b   Ross, Sarajane ^b   Buonaccorsi, Giovanni A ^a   Davies, Karen ^a   Hasan, Jurjees ^a   Thornton, Paula ^a   Del Puerto, Olivia ^c   Ferrara, Napoleone ^b   Van Bruggen, Nicholas ^b   Jayson, Gordon C ^a   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b GENENTECH INC   (United States)

^c ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; GADODIAMIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G6 31; OXALIPLATIN; PERFLUTREN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; COLORECTAL CANCER; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG MECHANISM; ECHOGRAPHY; EDEMA; EX VIVO STUDY; FEMALE; HUMAN; IN VIVO STUDY; LIVER METASTASIS; MICRO-COMPUTED TOMOGRAPHY; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA VOLUME; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR VASCULARIZATION;

ADOLESCENT; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70350721785     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0731     Document Type: Article

References (37)

1. Senger DR, Galli SJ, Dvorak AM , et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-985
2. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309 (Pubitemid 20066716)
3. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9: 669-676
4. Kerr DJ. Targeting angiogenesis in cancer: clinical development of bevacizumab. Nat Clin Pract Oncol 2004;1:39-43. (Pubitemid 40812647)
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342 (Pubitemid 38702844)
6. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small- cell lung cancer. N Engl J Med 2006;355: 2542-2550 (Pubitemid 44917502)
7. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-2676
8. Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 2004;22:4442-4445
9. O'Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007;96:189-195 (Pubitemid 46160619)
10. Jayson GC, Zweit J, Jackson A, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 2002;94:1484-1493 (Pubitemid 35251753)
11. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24:769-777
12. Drevs J, Siegert P, Medinger M, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007;25:3045-3054 (Pubitemid 47218051)
13. Hahn OM, Yang C, Medved M, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 2008; 26:4572-4578
14. Galbraith SM, Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21:2831-2842
15. Workman P, Aboagye EO, Chung YL, et al. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesistesting clinical trials of innovative therapies. J Natl Cancer Inst 2006;98:580-598 (Pubitemid 43904842)
16. O'Connor JP, Jackson A, Asselin MC, et al. Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. Lancet Oncol 2008;9: 766-776 (Pubitemid 352038315)
17. Liang WC, Wu X, Peale FV, et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 2006;281: 951-961
18. Shojaei F, Wu X, Zhong C, et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007;450:825-831 (Pubitemid 350231321)
19. Schwarz KQ, Bezante GP, Chen X, Mottley JG, Schlief R. Volumetric arterial flow quantification using echo contrast. An in vitro comparison of three ultrasonic intensity methods: radio frequency, video and Doppler. Ultrasound Med Biol 1993;19:447-460
20. Parker GJ, Roberts C, Macdonald A, et al. Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn Reson Med 2006;56: 993-1000. (Pubitemid 44691341)
21. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997;7:91-101.
22. Jackson A, Jayson GC, Li KL, et al. Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. Br J Radiol 2003;76:153-162 (Pubitemid 36553239)
23. Evelhoch JL, LoRusso PM, He Z, et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 2004;10:3650-3657 (Pubitemid 38697598)
24. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003;21: 3955-3964
25. Liu G, Rugo HS, Wilding G, et al. Dynamic contrast- enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005; 23:5464-5473 (Pubitemid 46300139)
26. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-232
27. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95. (Pubitemid 46075199)
28. Berry LR, BarckKH, Go MA, et al. Quantification of viable tumor microvascular characteristics by multispectral analysis. Magn Reson Med 2008;60:64-72.
29. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization; 1979.
30. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216
31. Padhani AR, Ollivier L. The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. Br J Radiol 2001;74:983-986
32. Leach MO, Brindle KM, Evelhoch JL, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005;92:1599-1610 (Pubitemid 40756468)
33. Karrison TG, Maitland ML, Stadler WM, Ratain MJ. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst 2007;99:1455-1461
34. Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009;6:327-338
35. Yuan F, Chen Y, Dellian M, et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996;93:14765-14770 (Pubitemid 26419043)
36. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147 (Pubitemid 38524883)
37. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-563 (Pubitemid 40017699)